Ovid develops small molecule medicines for brain disorders such as epilepsy, seizure disorders and psychosis. It last closed at $2.22 on Nov 17, down 7.50% on the day. The average 12-month price target from 3 analysts is $5.67 (+155.3% from the last close), with a high of $7.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $191K, the largest $191K.
Each firm's latest rating on OVID in the past 90 days
Average 12-month target
$5.67
▲ 155.3% upside
Based on 3 analysts who set a price target on OVID in the past 90 days. The average target is $5.67, with a high of $7.00 and a low of $5.00, compared with the last close of $2.22.
Low $5.00Avg $5.67High $7.00
Blue marker: last close $2.22
Highest target$7.00
Average target$5.67
Lowest target$5.00
Latest rating changes
Wolfe ResearchInitiated
Oct 15Buy$5
GuggenheimInitiated
Oct 5Buy$7
HC Wainwright & Co.Maintained
Sep 11Buy$5
OppenheimerMaintained
Aug 3Buy$9
Date
Firm
Action
Rating
Price target
Oct 15
Wolfe Research
Initiated
Buy
$5
Oct 5
Guggenheim
Initiated
Buy
$7
Sep 11
HC Wainwright & Co.
Maintained
Buy
$5
Aug 3
Oppenheimer
Maintained
Buy
$9
Loading…
Technical Analysis
OVID · as of the Nov 17 close · updated after every close
Turning down
The stock is 13% below its 20 day and 12% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the swing low (Jul 31) at $2.20, and the nearest resistance the Pivot at $2.26.
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 10.2%/day
Key levels
$3.1152 week high+40.1%
$2.55100 day average+14.9%
$2.5020 day average+12.6%
$2.4950 day average+12.2%
$2.49Swing high (Oct 12)+12.2%
$2.42200 day average+9.0%
$2.36Pivot R1+6.3%
$2.26Pivot+1.8%
$2.22Last close
$2.20Swing low (Jul 31)−0.9%
$2.12Pivot S1−4.5%
$1.2152 week low−45.5%
Indicators
RSI (14)
40.15
Middle of its range
Neutral
MACD
0.02
Below its signal line
Bearish
Stochastic
24.2
Middle of its range
Neutral
ADX (14)
22.4
Weak trend
Williams %R
-93.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-102.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.5%
Change over 10 sessions
Bearish
ATR (14)
$0.23
Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 18.1%/day
Key levels
$3.1152 week high+40.1%
$2.55100 day average+14.9%
$2.5020 day average+12.6%
$2.4950 day average+12.2%
$2.49Swing high (Oct 12)+12.2%
$2.42200 day average+9.0%
$2.36Pivot R1+6.3%
$2.26Pivot+1.8%
$2.22Last close
$2.20Swing low (Jul 31)−0.9%
$2.12Pivot S1−4.5%
$1.2152 week low−45.5%
Indicators
RSI (14)
45.46
Middle of its range
Neutral
MACD
0.03
Below its signal line
Bearish
Stochastic
48.8
Middle of its range
Neutral
ADX (14)
22.3
Weak trend
Williams %R
-87.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-82.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−17.5%
Change over 10 sessions
Bearish
ATR (14)
$0.40
Typical daily range, 18.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for OVID
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OVID did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OVID usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OVID has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OVID is in one of them and how their past OVID trades turned out.
Ovid is a biopharmaceutical company that develops small molecule medicines for disorders of the brain and nervous system. Its work centers on epilepsy, seizure disorders and psychosis, with medicines designed to calm overactive nerve cells. Its programs are in clinical trials, and the company aims to serve patients with seizure and psychiatric conditions that have few treatment options. Ovid is based in New York.